PRODUCT NAME

VELCADE® (bortezomib) for Injection
VELCADE® 3.5 mg Powder for Solution and for Injection

VELCADE® *is a registered trademark of Millennium Pharmaceuticals, Inc.*

DOSAGE FORMS AND STRENGTHS

VELCADE® (bortezomib) for Injection is supplied as individually cartoned 10 mL single use vials containing 3.5 mg of bortezomib as a white to off-white cake or powder.

- 3.5 mg single use vial

VELCADE® (bortezomib) for Injection is an antineoplastic agent available for intravenous injection (IV) or subcutaneous (SC) use. Each single use vial contains:

- 3.5 mg of bortezomib as a sterile lyophilized powder. Inactive ingredient: 35 mg mannitol, USP/EP (IV or SC use).

CLINICAL INFORMATION

Indications

VELCADE® (bortezomib) for Injection is indicated as part of combination therapy for the treatment of patients with previously untreated multiple myeloma.
VELCADE® (bortezomib) for Injection is indicated as monotherapy for the treatment of patients with multiple myeloma who have received at least 1 prior therapy.
VELCADE® (bortezomib) for Injection is indicated as monotherapy for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

VELCADE® (bortezomib) for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Dosage and Administration

VELCADE® may be administered:

- Intravenously (at a concentration of 1 mg/ml) as a 3 to 5 second bolus injection or
- Subcutaneously (at a concentration of 2.5 mg/ml)

Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.

At least 72 hours should elapse between consecutive doses of VELCADE®.

VELCADE® IS FOR INTRAVENOUS OR SUBCUTANEOUS USE ONLY. Intrathecal administration has resulted in death.

Monotherapy

Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma

Recommended Dosage

The recommended dose of VELCADE® is 1.3 mg/m^2/dose administered twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, VELCADE® may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35) (see *Clinical Trials* section for a description of dose administration during the trials). At least 72 hours should elapse between consecutive doses of VELCADE®.

Dose Modification and Re-initiation of Therapy

VELCADE® therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy as discussed below (see *Special Warnings And Special Precautions For Use*). Once the symptoms of the toxicity have resolved, VELCADE® therapy may be reinitiated at a 25% reduced dose (1.3 mg/m^2/dose reduced to 1.0 mg/m^2/dose; 1.0 mg/m^2/dose reduced to 0.7 mg/m^2/dose).

Table 1 contains the recommended dose modification for the management of patients who experience VELCADE®-related neuropathic pain and/or peripheral neuropathy. Severe autonomic neuropathy resulting in treatment interruption or discontinuation has been reported. Patients with pre-existing severe neuropathy should be treated with VELCADE® only after careful risk-benefit assessment.

Table 1: Recommended Dose Modification for VELCADE®-related Neuropathic Pain and/or Peripheral Sensory or Motor Neuropathy

Severity of Peripheral Neuropathy Signs and Symptoms [a]	Modification of Dose and Regimen
Grade 1 (asymptomatic, loss of deep tendon reflexes or parasthesia) without pain or loss of function	No action
Grade 1 with pain or Grade 2 (moderate symptoms; Limiting Instrumental Activities of Daily Living (ADL)) [b]	Reduce VELCADE® to 1.0 mg/m^2 OR Change VELCADE® treatment schedule to 1.3 mg/m^2 once per week
Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADL[c])	Withhold VELCADE® therapy until toxicity resolves. When toxicity resolves reinitiate with a reduced dose of VELCADE® at 0.7mg/m^2 once per week.
Grade 4 (life-threatening consequences; urgent intervention indicated)	Discontinue VELCADE®

[a] Grading based on NCI Common Toxicity Criteria CTCAE v4.0

[b] *Instrumental ADL*: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money etc.

[c] *Self care ADL*: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

Administration

VELCADE® is administered intravenously or subcutaneously. When administered intravenously, VELCADE® is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with 0.9% sodium chloride solution for

injection. For subcutaneous administration, the reconstituted solution is injected into the thighs (right or left) or abdomen (right or left). Injection sites should be rotated for successive injections.

If local injection site reactions occur following VELCADE® injection subcutaneously, a less concentrated VELCADE® solution (1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously, or changed to IV injection.

Combination Therapy

Previously Untreated Multiple Myeloma

Recommended Dosage in Combination with Melphalan and Prednisone

VELCADE® (bortezomib) for Injection is administered in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in **Table 2**. In Cycles 1-4, VELCADE® is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, VELCADE® is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of VELCADE®.

Table 2: Recommended Dosage Regimen for VELCADE® when used in combination with melphalan and prednisone for Patients with Previously Untreated Multiple Myeloma

Twice Weekly VELCADE® (Cycles 1-4)											
Week	1				2		3	4		5		6
Vc (1.3 mg/m^2)	Day 1	--	--	Day 4	Day 8	Day 11	rest period	Day 22	Day 25	Day 29	Day 32	rest period
m(9 mg/m^2) p(60 mg/m$^{2)}$	Day 1	Day 2	Day 3	Day 4	--	--	rest period	--	--	--	--	rest period

Once Weekly VELCADE® (Cycles 5-9)									
Week	1				2	3	4	5	6
Vc (1.3 mg/m$^{2)}$	Day 1	--	--	--	Day 8	rest period	Day 22	Day 29	rest period
m (9 mg/m^2) p (60 mg/m^2)	Day 1	Day 2	Day 3	Day 4	--	rest period	--	--	rest period

Vc = VELCADE®; m = melphalan, p=prednisone

Dose Management Guidelines for Combination Therapy with Melphalan and Prednisone

Dose modification and reinitiation of therapy when VELCADE® is administered in combination with melphalan and prednisone

Prior to initiating a new cycle of therapy:

- Platelet count should be ≥70 x 10^9/L and the absolute neutrophil count (ANC) should be ≥ 1.0 x 10^9/L
- Non-hematological toxicities should have resolved to Grade 1 or baseline

Table 3: Dose Modifications During Subsequent Cycles

Toxicity	**Dose modification or delay**
Hematological toxicity during a cycle:	
• If prolonged Grade 4 neutropenia or	Consider reduction of the melphalan dose by 25% in the

thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle	next cycle
• If platelet count ≤30 × 10^9/L or ANC ≤0.75 x 10^9/L on a VELCADE® dosing day (other than day 1)	VELCADE® dose should be withheld
• If several VELCADE® doses in a cycle are withheld (≥ 3 doses during twice weekly administration or ≥ 2 doses during weekly administration)	VELCADE® dose should be reduced by 1 dose level (from 1.3 mg/m^2 to 1 mg/m^2, or from 1 mg/m^2 to 0.7 mg/m^2)
Grade ≥ 3 non-hematological toxicities	VELCADE® therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline. Then, VELCADE® may be reinitiated with one dose level reduction (from 1.3 mg/m^2 to 1 mg/m^2, or from 1 mg/m^2 to 0.7 mg/m^2). For VELCADE®-related neuropathic pain and/or peripheral neuropathy, hold and/or modify VELCADE® as outlined in Table 1.

For additional information concerning melphalan and prednisone, see manufacturer's prescribing information.

Previously Untreated Mantle Cell Lymphoma Patients Not Eligible for Haematopoietic Stem Cell Transplantation

Recommended Dosage in Combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone

For VELCADE® dosage, see Monotherapy. Six VELCADE® cycles are administered. For patients with a response first documented at Cycle 6, two additional VELCADE® cycles are recommended.

The following medicinal products are administered on Day 1 of each VELCADE® 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/m^2, cyclophosphamide at 750 mg/m^2, and doxorubicin at 50 mg/m^2. Prednisone is administered orally at 100 mg/m^2 on Days 1, 2, 3, 4 and 5 of each treatment cycle.

Dose Adjustments during Treatment for Patients with Previously Untreated Mantle Cell Lymphoma

Prior to the first day of each cycle (other than Cycle 1):

- Platelet count should be ≥ 100 x 10^9/L and absolute neutrophil count (ANC) should be ≥ 1.5 x 10^9/L
- Hemoglobin should be ≥ 8 g/dL (≥ 4.96 mmol/L)
- Non-hematologic toxicity should have recovered to Grade 1 or baseline

VELCADE® treatment must be withheld at the onset of any Grade 3 non-hematological or Grade 3 hematological toxicities, excluding neuropathy (see also section 4.4). For dose adjustments, see **Table 4** below.

Table 4: Dose Adjustments during Treatment for Patients with Previously Untreated Mantle Cell Lymphoma

Toxicity	Posology modification or delay
Hematological toxicity	

Toxicity	Posology modification or delay
• ≥ Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count $< 10 \times 10^9$/L	VELCADE® therapy should be withheld for up to 2 weeks until the patient has an ANC $\geq 0.75 \times 10^9$/L and a platelet count $\geq 25 \times 10^9$/L. • If, after VELCADE® has been held, the toxicity does not resolve, as defined above, then VELCADE® must be discontinued. • If toxicity resolves i.e. patient has an ANC $\geq 0.75 \times 10^9$/L and a platelet count $\geq 25 \times 10^9$/L, VELCADE® dose should be reduced by 1 dose level (from 1.3 mg/m^2 to 1 mg/m^2, or from 1 mg/m^2 to 0.7 mg/m^2).
• If platelet counts $< 25 \times 10^9$/L. or ANC $< 0.75 \times 10^9$/L on a VELCADE® dosing day (other than Day 1)	VELCADE® dose should be withheld
Grade ≥ 3 non-hematological toxicities	VELCADE® therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better. Then, VELCADE® may be reinitiated with one dose level reduction (from 1.3 mg/m^2 to 1 mg/m^2, or from 1 mg/m^2 to 0.7 mg/m^2). For VELCADE®-related neuropathic pain and/or peripheral neuropathy, hold and/or modify VELCADE® as outlined in **Table 1**.

For dosing instructions for rituximab, cyclophosphamide, doxorubicin, or prednisone, see manufacturer's prescribing information.

Special Populations

Patients with Renal Impairment

The pharmacokinetics of VELCADE® are not influenced by the degree of renal impairment. Therefore, dosing adjustments of VELCADE® are not necessary for patients with renal insufficiency. Since dialysis may reduce VELCADE® concentrations, the drug should be administered after the dialysis procedure (see *Pharmacokinetic Properties*).

Patients with Hepatic Impairment

Patients with mild hepatic impairment do not require a starting dose adjustment and should be treated per the recommended VELCADE® dose. Patients with moderate or severe hepatic impairment should be started on VELCADE® at a reduced dose of 0.7 mg/m^2 per injection during the first cycle, and a subsequent dose escalation to 1.0mg/m^2 or further dose reduction to 0.5mg/m^2 may be considered based on patient tolerance (see **Table 5**).

Table 5: Recommended Starting Dose Modification for VELCADE® in Patients with Hepatic Impairment

Liver Function Test	Bilirubin Level	SGOT (AST) Levels	Modification of Starting Dose
Mild	≤1.0 x ULN	> ULN	None
	>1.0x-1.5xULN	Any	None
Moderate	>1.5x-3x ULN	Any	Reduce VELCADE® to 0.7mg/m^2 in the first cycle. Consider dose escalation to 1.0mg/m^2 or further dose reduction to
Severe	> 3x ULN	Any	

			0.5mg/m^2 in subsequent cycles based on patient tolerability

Abbreviations: SGOT = serum glutamic oxaloacetic transaminase;
AST = aspartate aminotransferase; ULN = upper limit of the normal range.

Contraindications

VELCADE® is contraindicated in patients with acute diffuse infiltrative pulmonary and pericardial disease and hypersensitivity to bortezomib, boron, or mannitol.

Warnings and Precautions

VELCADE® should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

There have been fatal cases of inadvertent intrathecal administration of VELCADE®. VELCADE® is for IV and subcutaneous use only. **DO NOT ADMINISTER VELCADE® INTRATHECALLY.**

Overall, the safety profile of patients treated with VELCADE® in monotherapy was similar to that observed in patients treated with VELCADE® in combination with melphalan and prednisone.

Peripheral Neuropathy

VELCADE® treatment causes a peripheral neuropathy (PN) that is predominantly sensory. However, cases of severe motor neuropathy with or without sensory peripheral neuropathy have been reported.

Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including ≥Grade 3) during treatment with VELCADE®. Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. In the Phase 3 study comparing VELCADE® IV vs SC the incidence of Grade ≥ 2 peripheral neuropathy events was 24% for SC and 41% for IV ($p = 0.0124$). Grade ≥ 3 peripheral neuropathy occurred in 6% of subjects in the SC treatment group, compared with 16% in the IV treatment group ($p = 0.0264$) (**Table 9**). Therefore, patients with pre-existing PN or at high risk of peripheral neuropathy may benefit from starting VELCADE® subcutaneously.

Patients experiencing new or worsening peripheral neuropathy may require a change in dose, schedule or route of administration to SC (see *Posology and Method of Administration*). Following dose adjustments, improvement in or resolution of peripheral neuropathy was reported in 51% of patients with ≥Grade 2 peripheral neuropathy in the single agent phase 3 multiple myeloma study of VELCADE® vs dexamethasone. Improvement in or resolution of peripheral neuropathy was reported in 73% of patients who discontinued due to Grade 2 neuropathy or who had ≥Grade 3 peripheral neuropathy in the phase 2 multiple myeloma studies.

The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.

Hypotension
In phase 2 and 3 single agent multiple myeloma studies, the incidence of hypotension (postural, orthostatic, and hypotension Not Otherwise Specified) was 11% to 12%. These events are observed throughout therapy. Caution should be used when treating patients with a history of syncope, patients receiving medications known to be associated with hypotension, and patients who are dehydrated. Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics (see *Undesirable Effects*).

Cardiac Disorders
Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. Patients with risk factors for, or existing heart disease should be closely monitored. In the single agent phase 3 multiple myeloma study of VELCADE® vs dexamethasone, the incidence of any treatment-emergent cardiac disorder was 15% and 13% respectively. The incidence of heart failure events (acute pulmonary edema, cardiac failure, congestive cardiac failure, cardiogenic shock, pulmonary edema) was similar in the VELCADE® and dexamethasone groups, 5% and 4%, respectively.

There have been isolated cases of QT-interval prolongation in clinical studies; causality has not been established.

Hepatic Events
Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Other reported hepatic events include increases in liver enzymes, hyperbilirubinemia, and hepatitis. Such changes may be reversible upon discontinuation of VELCADE®. There is limited re-challenge information in these patients.

Pulmonary Disorders
There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome (ARDS) in patients receiving VELCADE®. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. In the event of new or worsening pulmonary symptoms, a prompt comprehensive diagnostic evaluation should be performed and patients treated appropriately.

In a clinical trial, two patients given high-dose cytarabine ($2g/m^2$ per day) by continuous infusion with daunorubicin and VELCADE® for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. Therefore, this specific regimen with concomitant administration with high-dose cytarabine ($2g/m^2$ per day) by continuous infusion over 24 hours is not recommended.

There have been rare reports of pulmonary hypertension associated with VELCADE® administration in the absence of left heart failure or significant pulmonary disease.

Laboratory Tests

Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE®.

Thrombocytopenia/Neutropenia

VELCADE® is associated with thrombocytopenia and neutropenia (see *Undesirable Effects*). Platelets were lowest at Day 11 of each cycle of VELCADE® treatment and typically recovered to baseline by the next cycle. The cyclical pattern of platelet count decrease and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in any of the regimens studied.

Platelet counts should be monitored prior to each dose of VELCADE®. VELCADE® therapy should be held when the platelet count is <25,000/µL (see *Posology and Method of Administration* and *Undesirable Effects*). There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE®. Transfusions and supportive care may be considered.

In the single-agent multiple myeloma study of VELCADE® vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in **Table 6**. The incidence of significant bleeding events (≥ Grade 3) was similar on both the VELCADE® (4%) and dexamethasone (5%) arms.

Table 6: Severity of Thrombocytopenia Related to Pretreatment Platelet Count in the Single Agent Phase 3 Multiple Myeloma Study of VELCADE® vs Dexamethasone

Pretreatment Platelet Count[a]	Number of Patients (N=331)[b]	Number (%) of Patients with Platelet Count <10,000/µL	Number (%) of Patients with Platelet Count 10,000-25,000/µL
≥75,000/µL	309	8 (3%)	36 (12%)
≥ 50,000/µL-<75,000/µL	14	2 (14%)	11 (79%)
≥10,000/µL-<50,000/µL	7	1 (14%)	5 (71%)

[a] A baseline platelet count of 50,000/µL was required for study eligibility.
[b] Data were missing at baseline for 1 patient

In the combination study of VELCADE® with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia adverse events (≥ Grade 4) was 32% versus 2% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm. The incidence of bleeding adverse events (≥ Grade 3) was 1.7% (4 patients) in the VcR-CAP arm and was 1.2% (3 patients) in the R-CHOP arm.

There were no deaths due to bleeding events in either arm. There were no CNS bleeding events in the VcR-CAP arm; there was 1 bleeding event in the R-CHOP arm. Platelet transfusions were given to 23% of the patients in the VcR-CAP arm and 3% of the patients in the R-CHOP arm.

The incidence of neutropenia (≥ Grade 4) was 70% in the VcR-CAP arm and was 52% in the R-CHOP arm. The incidence of febrile neutropenia (≥ Grade 4) was 5% in the VcR-CAP arm and

was 6% in the R-CHOP arm. Colony-stimulating factor support was provided at a rate of 78% in the VcR-CAP arm and 61% in the R-CHOP arm.

Gastrointestinal Adverse Events

VELCADE® treatment can cause nausea, diarrhea, constipation, and vomiting (see *Undesirable Effects*) sometimes requiring use of antiemetics and antidiarrheal medications. Fluid and electrolyte replacement should be administered to prevent dehydration. Since patients receiving VELCADE® therapy may experience vomiting and/or diarrhea, patients should be advised regarding appropriate measures to avoid dehydration. Patients should be instructed to seek medical advice if they experience symptoms of dizziness, light headedness or fainting spells.

Tumor Lysis Syndrome

Because VELCADE® is a cytotoxic agent and can rapidly kill malignant cells, the complications of tumor lysis syndrome may occur. Patients at risk of tumor lysis syndrome are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

Patients with Hepatic Impairment

Bortezomib is metabolized by liver enzymes. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment, these patients should be treated with VELCADE® at reduced starting doses and closely monitored for toxicities (see *Posology and Method of Administration* and *Pharmacokinetic Properties*).

Posterior Reversible Encephalopathy Syndrome (PRES)

There have been reports of PRES in patients receiving VELCADE®. PRES is a rare, reversible, neurological disorder, which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. Brain imaging, preferably MRI (Magnetic Resonance Imaging), is used to confirm the diagnosis. In patients developing PRES, discontinue VELCADE®. The safety of reinitiating VELCADE® therapy in patients previously experiencing PRES is not known.

Seizures

Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy. Special care is required when treating patients with any risk factors for seizures.

Renal Impairment

Renal complications are frequent in patients with multiple myeloma. Patients with renal impairment should be monitored closely.

Concomitant Medicinal Products

Patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors. Caution should be exercised when bortezomib is combined with CYP3A4 or CYP2C19 substrates. Normal liver function should be confirmed and caution should be exercised in patients receiving oral hypoglycemic.

Potentially Immunocomplex-mediated Reactions

Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly. Bortezomib should be discontinued if serious reactions occur.

Thrombotic Microangiopathy

Cases, sometimes fatal, of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/haemolytic uremic syndrome (TTP/HUS), have been reported in the postmarketing setting in patients who received bortezomib. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop bortezomib and evaluate. If the diagnosis of TTP/HUS is excluded, consider restarting bortezomib. The safety of reinitiating bortezomib therapy in patients previously experiencing TTP/HUS is not known.

Interactions

In vitro and animal *ex vivo* studies indicate that bortezomib is a weak inhibitor of cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4. Based on limited contribution (7%) of CYP2D6 to the metabolism of bortezomib, the CYP2D6 poor metabolizer phenotype is not expected to affect the overall disposition of bortezomib.

A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of VELCADE®, showed a bortezomib AUC mean increase of 35%, based on data from 12 patients. Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4-inhibitors (e.g. ketoconazole, ritonavir).

In a drug-drug interaction study assessing the effect of omeprazole, a potent inhibitor of CYP2C19, on the pharmacokinetics of VELCADE®, there was no significant effect on the pharmacokinetics of bortezomib, based on data from 17 patients.

A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of VELCADE® showed a mean bortezomib AUC reduction of 45% based on data from 6 patients. The concomitant use of VELCADE® with strong CYP3A4 inducers is therefore not recommended, as efficacy may be reduced. Examples of CYP3A4 inducers are rifampicin, carbamazepine, phenytoin, phenobarbital and St. John's Wort. In the same drug-drug interaction study, the effect of dexamethasone, a weaker CYP3A4 inducer was assessed. There was no significant effect on bortezomib pharmacokinetics based on data from 7 patients.

A drug-drug interaction study assessing the effect of melphalan-prednisone on VELCADE® showed a 17% increase in mean bortezomib AUC based on data from 21 patients. This is not considered clinically relevant.

During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving VELCADE® treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.

Patients should be cautioned about the use of concomitant medications that may be associated with peripheral neuropathy (such as amiodarone, anti-virals, isoniazid, nitrofurantoin, or statins), or with a decrease in blood pressure.

Drug Laboratory Test Interactions
None known.

Pregnancy and Breast-feeding
Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE®.

Bortezomib was not teratogenic in nonclinical developmental toxicity studies in rats and rabbits at the highest dose tested (0.075 mg/kg(0.5 mg/m^2) in the rat and 0.05 mg/kg(0.6 mg/m^2) in the rabbit) when administered during organogenesis. These dosages are approximately half the clinical dose of 1.3 mg/m^2 based on body surface area.

Pregnant rabbits given bortezomib during organogenesis at a dose of 0.05mg/kg (0.6 mg/m^2) experienced significant post-implantation loss and decreased number of live fetuses. Live fetuses from these litters also showed significant decreases in fetal weight. The dose is approximately 0.5 times the clinical dose of 1.3 mg/m^2 based on body surface area.

No placental transfer studies have been conducted with bortezomib. There are no adequate and well-controlled studies in pregnant women. If VELCADE® is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.

Patients should be advised to use effective contraceptive measures to prevent pregnancy.

Nursing Mothers
It is not known whether bortezomib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from VELCADE®, women should be advised against breast feeding while being treated with VELCADE®.

Effects on Ability to Drive and use Machines
VELCADE® may cause fatigue, dizziness, syncope, orthostatic/postural hypotension or blurred vision. Patients should be advised not to drive or operate machinery if they experience these symptoms.

Adverse Reactions
Summary of Clinical Trials of VELCADE® IV in Patients with Relapsed/Refractory Multiple Myeloma

The safety and efficacy of VELCADE® were evaluated in 3 studies at the recommended dose of 1.3 mg/m^2. These included a phase 3 randomized, comparative study, versus dexamethasone of 669 patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy (M34101-039); a phase 2 single arm, open-label, multicenter study of 202 patients who had received at least 2 prior therapies and demonstrated disease progression on their most recent therapy (M34100-025); and a phase 2 dose-response clinical study in relapsed multiple myeloma for patients who had progressed or relapsed on or after first line therapy with VELCADE® 1.0 mg/m^2 or 1.3 mg/m^2 (M34100-024).

Table 7: VELCADE® Adverse Drug Reactions in Phase 2 and Phase 3 Relapsed/Refractory Multiple Myeloma Studies

	Study No.	
MedDRA System Organ Class Preferred Term	039 (N=331)	024/025 (N=228[a])
Blood and lymphatic system disorders		
Thrombocytopenia	115 (35%)	97 (43%)
Anemia	87 (26%)	74 (32%)
Neutropenia	62 (19%)	55 (24%)
Leucopenia	24 (7%)	15 (7%)
Lymphopenia	15 (5%)	11 (5%)
Pancytopenia	2 (<1%)	6 (3%)
Febrile Neutropenia	1 (<1%)	1 (<1%)
Cardiac disorders		
Arrhythmias	4 (1%)	2 (<1%)
Tachycardia	9 (3%)	17 (7%)
Atrial Fibrillation	6 (2%)	2 (<1%)
Palpitations	5 (2%)	4 (2%)
Acute Development or exacerbation of cardiac failure, including CHF	7 (2%)	8 (4%)
Pulmonary edema	6 (2%)	3 (1%)
Cardiogenic shock[b]	1 (<1%)	-
New onset of decreased left ventricular ejection fraction	1 (<1%)	-
Atrial Flutter	1 (<1%)	-
Bradycardia	3 (<1%)	1 (<1%)
Ear & labyrinth disorders		
Hearing Impairment	1 (<1%)	1 (<1%)
Eye disorders		
Blurred Vision	9 (3%)	25 (11%)
Conjunctival infection and irritation	14 (4%)	7 (3%)
Gastrointestinal (GI) disorders		
Constipation	140 (42%)	97 (43%)
Diarrhea	190 (57%)	116 (51%)
Nausea	190 (57%)	145 (64%)
Vomiting	117 (35%)	82 (36%)
Gastrointestinal and abdominal pain, excluding oral and throat	80 (24%)	48 (21%)
Dyspepsia	32 (10%)	30 (13%)
Pharyngolaryngeal pain	25 (8%)	19 (8%)

	Study No.	
MedDRA System Organ Class Preferred Term	039 (N=331)	024/025 (N=228[a])
Gastroesophageal reflux	10 (3%)	1 (<1%)
Eructation	2 (<1%)	4 (2%)
Abdominal distension	14 (4%)	13 (6%)
Stomatitis and mouth ulceration	24 (7%)	10 (4%)
Dysphagia	4 (1%)	5 (2%)
GI hemorrhage (upper and lower GI tract)[b]	7 (2%)	3 (1%)
Rectal hemorrhage (includes hemorrhagic diarrhea)	7 (2%)	3 (1%)
Tongue ulceration	2 (<1%)	1 (<1%)
Retching	3 (<1%)	2 (<1%)
Upper GI hemorrhage	1 (<1%)	-
Hematemesis	1 (<1%)	-
Oral mucosal petechiae	3 (<1%)	-
Ileus Paralytic	1 (<1%)	2 (<1%)
General disorders and administration site conditions		
Asthenic conditions	201 (61%)	149 (65%)
weakness	40 (12%)	44 (19%
fatigue	140 (42%)	118 (52%)
lethargy	12 (4%)	9 (4%)
malaise	13 (4%)	22 (10%)
Pyrexia	116 (35%)	82 (36%)
Rigors	37 (11%)	27 (12%)
Edema of the lower limbs	35 (11%)	27 (12%)
Neuralgia	21 (6%)	5 (2%)
Chest Pain	26 (8%)	16 (7%)
Injection site pain and irritation	1 (<1%)	1 (<1%)
Injection site phlebitis	1 (<1%)	1 (<1%)
Hepatobiliary disorders		
Hyperbilirubinemia	1 (<1%)	-
Abnormal liver function tests	3 (<1%)	2 (<1%)
Hepatitis	2 (<1%) in study M34101-040[c]	-
Immune system disorders		
Drug hypersensitivity	1 (<1%)	1 (<1%)
Infections and infestations		
Upper respiratory tract infection	26 (8%)	41 (18%)
Nasopharyngitis	45 (14%)	17 (7%)
Lower respiratory tract and lung infections	48 (15%)	29 (13%)
Pneumonia[b]	21 (6%)	23 (10%)
Herpes zoster (including multidermatomal or disseminated)	42 (13%)	26 (11%)
Herpes simplex	25 (8%)	13 (6%)
Bronchitis	26 (8%)	6 (3%)
Postherpetic neuralgia	4 (1%)	1 (<1%)
Sinusitis	14 (4%)	15 (7%)
Pharyngitis	6 (2%)	2 (<1%)
Oral candidiasis	6 (2%)	3 (1%)
Urinary tract infection	13 (4%)	14 (6%)

	Study No.	
MedDRA System Organ Class Preferred Term	039 (N=331)	024/025 (N=228[a])
Catheter related infection	10 (3%)	6 (3%)
Sepsis and bacteremia[b]	9 (3%)	9 (4%)
Gastroenteritis	7 (2%)	-
Injury, poisoning, and procedural complications		
Catheter related complication	7 (2%)	8 (4%)
Investigations		
Increased ALT	3 (<1%)	10 (4%)
Increased AST	5 (2%)	12 (5%)
Increased alkaline phosphatase	6 (2%)	8 (4%)
Increased GGT	1 (<1%)	4 (2%)
Metabolism and nutritional disorders		
Decreased appetite and anorexia	112 (34%)	99 (43%)
Dehydration	24 (7%)	42 (18%)
Hyperglycemia	5 (2%)	16 (7%)
Hypoglycemia	7 (2%)	4 (2%)
Hyponatremia	8 (2%)	18 (8%)
Tumor Lysis Syndrome	2 (<1%) in study M34101-040[c]	-
Musculoskeletal and connective tissue disorders		
Pain in limb	50 (15%)	59 (26%)
Myalgia	39 (12%)	32 (14%)
Arthralgia	45 (14%)	60 (26%)
Nervous system disorders		
Peripheral neuropathy[d]	120 (36%)	84 (37%)
Paresthesia and dysesthesia	91 (27%)	53 (23%)
Dizziness, excluding vertigo	45 (14%)	48 (21%)
Headache	85 (26%)	63 (28%)
Dysgeusia	17 (5%)	29 (13%)
Polyneuropathy	9 (3%)	1 (<1%)
Syncope	8 (2%)	17 (7%)
Convulsions	4 (1%)	-
Loss of consciousness	2 (<1%)	-
Ageusia	2 (<1%)	-
Psychiatric disorders		
Anxiety	31 (9%)	32 (14%)
Renal and urinary disorders		
Renal Impairment and Failure	21 (6%)	21 (9%)
Difficulty in micturition	2 (1%)	3 (1%)
Hematuria	5 (2%)	4 (2%)
Respiratory, thoracic, and mediastinal disorders		
Epistaxis	21 (6%)	23 (10%)
Cough	70 (21%)	39 (17%)
Dyspnea	65 (20%)	50 (22%)
Exertional dyspnea	21 (6%)	18 (8%)
Pleural effusion	4 (1%)	9 (4%)
Rhinorrhoea	4 (1%)	14 (6%)
Hemoptysis	3 (<1%)	2 (<1%)
Skin and subcutaneous tissue disorders		
Skin rash, which can be pruritic, erythematous, and can include	61 (18%)	47 (21%)

	Study No.	
MedDRA System Organ Class Preferred Term	039 (N=331)	024/025 (N=228[a])
evidence of leukocytoclastic vasculitis		
Urticaria	7 (2%)	5 (2%)
Vascular disorders		
Hypotension	20 (6%)	27 (12%)
Orthostatic/postural hypotension	14 (4%)	8 (4%)
Petechiae	6 (2%)	7 (3%)
Cerebral hemorrhage[b]	1 (<1%)	-

[a] *All 228 patients received* VELCADE® *at a dose of* 1.3 mg/m^2

[b] *includes fatal outcome*

[c] *A study of* VELCADE® *at the recommended dose of* 1.3 mg/m^2 *in multiple myeloma patients who experienced progressive disease after receiving at least four previous therapies or after receiving high-dose dexamethasone in Protocol M34101-039*

[d] *Including all preferred terms under the MedDRA HLT "peripheral neuropathy NEC"*

Serious Adverse Events (SAEs) and Events Leading to Treatment Discontinuation in the Phase 3 Multiple Myeloma Study

Serious adverse events are defined as any event, regardless of causality, that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability, or is deemed to be an important medical event. A total of 144 (44%) patients from the VELCADE® treatment arm experienced an SAE during the study. The most commonly reported SAEs in the VELCADE® treatment arm were pyrexia (6%), diarrhea (5%), dyspnea and pneumonia (4%), and vomiting (3%). 84 (25%) of 331 patients in the VELCADE® treatment group were discontinued from treatment due to adverse events assessed as drug-related by the investigators. Among the 331 VELCADE® treated patients, the most commonly reported drug-related event leading to discontinuation was peripheral neuropathy (8%). Four deaths were considered to be VELCADE® related in the phase 3 multiple myeloma study: 1 case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest.

Non-randomized Phase 2 Clinical Studies

Serious Adverse Events (SAEs)

A total of 113 (50%) of 228 patients in the phase 2 studies experienced SAEs during the studies. The most commonly reported SAEs included pyrexia and pneumonia (each 7%), diarrhea (6%), vomiting and dehydration (each 5%) and nausea (4%).

In phase 2 clinical studies, adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (5%), thrombocytopenia (4%), and diarrhea and fatigue (each 2%).

Two deaths were reported and considered by the investigator to be possibly related to study drug: 1 case pulmonary arrest and 1 case of respiratory failure.

Summary of Clinical Trials of VELCADE® IV vs SC in Patients with Relapsed Multiple Myeloma

The safety and efficacy of VELCADE® SC were evaluated in one Phase 3 study at the recommended dose of 1.3 mg/m^2. This was a randomized, comparative study of VELCADE® IV vs SC in 222 patients with relapsed multiple myeloma.

Table 8: Incidence of VELCADE® Adverse Drug Reactions reported in ≥ 10% of patients in the Phase 3 Relapsed Multiple Myeloma Study comparing VELCADE® IV and SC

	IV (N = 74)			SC (N = 147)		
MedDRA System Organ Class	Total	Toxicity Grade, n (%)		Total	Toxicity Grade, n (%)	
Preferred Term	n (%)	3	≥ 4	n (%)	3	≥ 4
Blood and lymphatic system disorders						
Anaemia	26 (35)	6 (8)	0	53 (36)	14 (10)	4 (3)
Leukopenia	16 (22)	4 (5)	1 (1)	29 (20)	9 (6)	0
Neutropenia	20 (27)	10 (14)	3 (4)	42 (29)	22 (15)	4 (3)
Thrombocytopenia	27 (36)	8 (11)	6 (8)	52 (35)	12 (8)	7 (5)
Gastrointestinal disorders						
Abdominal pain	8 (11)	0	0	5 (3)	1 (1)	0
Abdominal pain upper	8 (11)	0	0	3 (2)	0	0
Constipation	11 (15)	1 (1)	0	21 (14)	1 (1)	0
Diarrhoea	27 (36)	3 (4)	1 (1)	35 (24)	2 (1)	1 (1)
Nausea	14 (19)	0	0	27 (18)	0	0
Vomiting	12 (16)	0	1 (1)	17 (12)	3 (2)	0
General disorders and administration site conditions						
Asthenia	14 (19)	4 (5)	0	23 (16)	3 (2)	0
Fatigue	15 (20)	3 (4)	0	17 (12)	3 (2)	0
Pyrexia	12 (16)	0	0	28 (19)	0	0
Infections and infestations						
Herpes zoster	7 (9)	1 (1)	0	16 (11)	2 (1)	0
Metabolism and nutrition disorders						
Decreased appetite	7 (9)	0	0	14 (10)	0	0
Musculoskeletal and connective tissue disorders						
Pain in extremity	8 (11)	2 (3)	0	8 (5)	1 (1)	0
Nervous system disorders						
Headache	8 (11)	0	0	5 (3)	0	0
Neuralgia	17 (23)	7 (9)	0	35 (24)	5 (3)	0
Peripheral sensory neuropathy	36 (49)	10 (14)	1 (1)	51 (35)	7 (5)	0
Psychiatric disorders						
Insomnia	8 (11)	0	0	18 (12)	0	0
Respiratory, thoracic and mediastinal disorders						
Dyspnoea	9 (12)	2 (3)	0	11 (7)	2 (1)	0

Note: Percentages in 'Total' column for each group calculated with the number of subjects in each group as denominator.
Percentages of toxicity grade sub-groups calculated with the number of subjects in each group as denominator.

Although, in general safety data were similar for the IV and SC treatment groups, the following table highlights differences larger than 10% in the overall incidence of adverse drug reactions between the two treatment arms.

Table 9: Incidence of Adverse Drug Reactions with >10% Difference in Overall Incidence between Treatment Arms in the Phase 3 Relapsed Multiple Myeloma Study comparing VELCADE® IV and SC, by Toxicity Grade and Discontinuation

	IV (N = 74)			SC (N = 147)		
MedDRA System Organ Class	Category, n (%)			Category, n (%)		
MedDRA High Level Term	TEAE	G ≥ 3	Disc	TEAE	G ≥ 3	Disc
All subjects with TEAE	73 (99)	52 (70)	20 (27)	140 (95)	84 (57)	33 (22)
Gastrointestinal disorders						
Diarrhoea (excl infective)	27 (36)	4 (5)	1 (1)	35 (24)	3 (2)	1 (1)
Gastrointestinal and abdominal pains (excl oral and throat)	14 (19)	0	0	9 (6)	1 (1)	0
General disorders and administration site conditions						
Asthenic conditions	29 (39)	7 (9)	1 (1)	40 (27)	6 (4)	2 (1)
Infections and infestations						
Upper respiratory tract infections	19 (26)	2 (3)	0	20 (14)	0	0
Nervous system disorders						
Peripheral neuropathies [a]	39 (53)	12 (16)	10 (14)	56 (38)	9 (6)	9 (6)

[a] Represents the high level term
TEAE = Treatment-Emergent Adverse Event; G ≥ 3 = Toxicity Grade greater than or equal to 3
Disc = Discontinuation of any study drug

Patients who received VELCADE® subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment-emergent adverse drug reactions that were grade 3 or higher in toxicity (57% vs 70% respectively), and a 5% lower incidence of discontinuation of VELCADE® (22% vs 27%). The overall incidence of diarrhea (24% for the SC arm vs 36% for the IV arm), gastrointestinal and abdominal pain (6% for the SC arm vs 19% for the IV arm), asthenic conditions (27% for SC arm vs 39% for IV arm), upper respiratory tract infections (14% SC arm vs 26% IV arm) and peripheral neuropathy NEC (38% SC arm vs 53% IV arm) were 12%-15% lower in the subcutaneous group than the intravenous group. In addition, the incidence of peripheral neuropathies that were grade 3 or higher in toxicity was 10% lower (6% for SC vs 16% for IV), and the discontinuation rate due to peripheral neuropathies was 8% lower for the subcutaneous group (5%) as compared to the intravenous group (12%).

Six percent of patients were reported to have had an adverse local reaction to SC administration, mostly redness. Only 2 (1%) subjects were reported as having severe reactions. These severe local reactions were 1 case of pruritus and 1 case of redness. These reactions seldom led to dose modifications and all resolved in a median of 6 days.

Summary of Clinical Trials in Patients with Previously Untreated Multiple Myeloma

The following table describes safety data from 340 patients with previously untreated multiple myeloma who received VELCADE® IV (1.3 mg/m^2) in combination with melphalan (9 mg/m^2) and prednisone (60 mg/m^2) in a prospective phase 3 study.

Table 10: Treatment-Emergent Drug-Related Adverse Events reported in ≥ 10% of patients treated with VELCADE® IV in combination with melphalan and prednisone

	Vc-MP (n=340)			MP (n=337)		
MedDRA System Organ Class	Total	Toxicity Grade, n (%)		Total	Toxicity Grade, n (%)	
Preferred Term	n (%)	3	≥4	n (%)	3	≥4
Blood and Lymphatic System Disorders						
Thrombocytopenia	164 (48)	60 (18)	57 (17)	140 (42)	48 (14)	39 (12)
Neutropenia	160 (47)	101 (30)	33 (10)	143 (42)	77 (23)	42 (12)
Anemia	109 (32)	41 (12)	4 (1)	156 (46)	61 (18)	18 (5)
Leukopenia	108 (32)	64 (19)	8 (2)	93 (28)	53 (16)	11 (3)
Lymphopenia	78 (23)	46 (14)	17 (5)	51 (15)	26 (8)	7 (2)
Gastrointestinal Disorders						
Nausea	134 (39)	10 (3)	0	70 (21)	1 (<1)	0
Diarrhea	119 (35)	19 (6)	2 (1)	20 (6)	1 (<1)	0
Vomiting	87 (26)	13 (4)	0	41 (12)	2 (1)	0
Constipation	77 (23)	2 (1)	0	14 (4)	0	0
Abdominal Pain Upper	34 (10)	1 (<1)	0	20 (6)	0	0
Nervous System Disorders						
Peripheral Neuropathy	156 (46)	42 (12)	2 (1)	4 (1)	0	0
Neuralgia	117 (34)	27 (8)	2 (1)	1 (<1)	0	0
Paresthesia	42 (12)	6 (2)	0	4 (1)	0	0
General Disorders and Administration Site Conditions						
Fatigue	85 (25)	19 (6)	2 (1)	48 (14)	4 (1)	0
Asthenia	54 (16)	18 (5)	0	23 (7)	3 (1)	0
Pyrexia	53 (16)	4 (1)	0	19 (6)	1 (<1)	1 (<1)
Infections and Infestations						
Herpes Zoster	39 (11)	11 (3)	0	9 (3)	4 (1)	0
Metabolism and Nutrition Disorders						
Anorexia	64 (19)	6 (2)	0	19 (6)	0	0
Skin and Subcutaneous Tissue Disorders						
Rash	38 (11)	2 (1)	0	7 (2)	0	0
Psychiatric Disorders						
Insomnia	35 (10)	1 (<1)	0	21 (6)	0	0

Herpes zoster virus reactivation

Physicians should consider using antiviral prophylaxis in patients being treated with VELCADE®. In the phase 3 study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with VcMP compared with MP (14% vs 4% respectively). Antiviral prophylaxis was administered to 26% of the patients in the VcMP arm. The incidence of herpes zoster among patients in the VcMP treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.

Summary of the Clinical Trial in Patients with Relapsed Mantle Cell Lymphoma

Safety data for patients with relapsed mantle cell lymphoma were evaluated in a phase 2 study [M34103-053 (PINNACLE)], which included 155 patients treated with VELCADE® at the recommended dose of 1.3 mg/m^2. The safety profile of VELCADE® in these patients was similar to that observed in patients with multiple myeloma. Notable differences between the two patient populations were that thrombocytopenia, neutropenia, anemia, nausea, vomiting and pyrexia were reported more often in the patients with multiple myeloma than in those with mantle cell lymphoma; whereas peripheral neuropathy, rash and pruritus were higher among patients with mantle cell lymphoma compared to patients with multiple myeloma.

Summary of Clinical Trial in Patients with Previously Untreated Mantle Cell Lymphoma

Table 11 describes safety data from 240 patients with previously untreated mantle cell lymphoma who received VELCADE® (1.3 mg/m^2) administered IV in combination with rituximab (375 mg/m^2), cyclophosphamide (750 mg/m^2), doxorubicin (50 mg/m^2), and prednisone (100 mg/m^2) (VcR-CAP) in a prospective randomized study.

The incidences of Grade ≥ 3 bleeding events were similar between the 2 arms (4 patients in the VcR-CAP arm and 3 patients in the R-CHOP arm). All of the Grade ≥ 3 bleeding events resolved without sequelae in the VcR-CAP arm.

Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the R-CHOP arm. Respiratory tract and lung infections were reported, with the predominant preferred term of pneumonia (VcR-CAP 8% versus R-CHOP 5%).

The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

Table 11: Most Commonly Reported Adverse Reactions (≥ 5%) with Grades 3 and ≥ 4 Intensity in the Mantle Cell Lymphoma Study of VcR-CAP versus R-CHOP (N=482) (Study LYM-3002)

	VcR-CAP n=240			R-CHOP n=242		
System Organ Class Preferred Term	Total n (%)	Toxicity Grade 3 n (%)	Toxicity Grade ≥4 n (%)	Total n (%)	Toxicity Grade 3 n (%)	Toxicity Grade ≥4 n (%)
Blood and lymphatic system disorders						
Neutropenia	209 (87)	32 (13)	168 (70)	172 (71)	31 (13)	125 (52)
Leukopenia	116 (48)	34 (14)	69 (29)	87 (36)	39 (16)	27 (11)
Anaemia	106 (44)	27 (11)	4 (2)	71 (29)	23 (10)	4 (2)
Thrombocytopenia	172 (72)	59 (25)	76 (32)	42 (17)	9 (4)	3 (1)
Febrile neutropenia	41 (17)	24 (10)	12 (5)	33 (14)	17 (7)	15 (6)
Lymphopenia	68 (28)	25 (10)	36 (15)	28 (12)	15 (6)	2 (1)
Nervous system disorders						
Peripheral sensory neuropathy	53 (22)	11 (5)	1 (< 1)	45 (19)	6 (3)	0
Neuropathy peripheral	18 (8)	4 (2)	0	18 (7)	2 (1)	0
Hypoaesthesia	14 (6)	3 (1)	0	13 (5)	0	0
Paraesthesia	14 (6)	2 (1)	0	11 (5)	0	0
Neuralgia	25 (10)	9 (4)	0	1 (< 1)	0	0

	VcR-CAP n=240			R-CHOP n=242		
System Organ Class Preferred Term	Total n (%)	Toxicity Grade 3 n (%)	Toxicity Grade ≥4 n (%)	Total n (%)	Toxicity Grade 3 n (%)	Toxicity Grade ≥4 n (%)
General disorders and administration site conditions						
Fatigue	43 (18)	11 (5)	1 (< 1)	38 (16)	5 (2)	0
Pyrexia	48 (20)	7 (3)	0	23 (10)	5 (2)	0
Asthenia	29 (12)	4 (2)	1 (< 1)	18 (7)	1 (< 1)	0
Oedema peripheral	16 (7)	1 (< 1)	0	13 (5)	0	0
Gastrointestinal disorders						
Nausea	54 (23)	1 (< 1)	0	28 (12)	0	0
Constipation	42 (18)	1 (< 1)	0	22 (9)	2 (1)	0
Stomatitis	20 (8)	2 (1)	0	19 (8)	0	1 (< 1)
Diarrhoea	59 (25)	11 (5)	0	11 (5)	3 (1)	1 (< 1)
Vomiting	24 (10)	1 (< 1)	0	8 (3)	0	0
Abdominal distension	13 (5)	0	0	4 (2)	0	0
Infections and infestations						
Pneumonia	20 (8)	8 (3)	5 (2)	11 (5)	5 (2)	3 (1)
Skin and subcutaneous tissue disorders						
Alopecia	31 (13)	1 (< 1)	1 (< 1)	33 (14)	4 (2)	0
Metabolism and nutrition disorders						
Hyperglycaemia	10 (4)	1 (< 1)	0	17 (7)	10 (4)	0
Decreased appetite	36 (15)	2 (1)	0	15 (6)	1 (< 1)	0
Hypokalaemia	11 (5)	3 (1)	1 (< 1)	6 (2)	1 (< 1)	0
Vascular disorders						
Hypertension	15 (6)	1 (< 1)	0	3 (1)	0	0
Psychiatric disorders						
Insomnia	16 (7)	1 (< 1)	0	8 (3)	0	0

Key: R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP=VELCADE®, rituximab, cyclophosphamide, doxorubicin, and prednisone.

Post-Marketing Experience

Clinically significant adverse drug reactions are listed here if they have not been reported above.

The frequencies provided below reflect reporting rates of adverse drug reactions from the worldwide post-marketing experience with VELCADE®. The frequencies provided below reflect reporting rates and precise estimates of incidence cannot be made.

These adverse drug reactions are ranked by frequency, using the following convention: Very common (≥1/10), common (≥1/100 and < 1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and < 1/1000), very rare (<1/10,000, including isolated reports).

Table 12: Post-marketing Reports of Adverse Reactions

Blood and lymphatic system disorders	
Disseminated intravascular coagulation	Rare
Thrombotic microangiopathy	Very Rare

Cardiac disorders	
Atrioventricular block complete, cardiac tamponade	Rare
Ear and labyrinth disorders	
Deafness bilateral	Rare
Eye disorders	
Ophthalmic herpes, optic neuropathy, blindness	Rare
Chalazion/blepharitis	Rare
Gastrointestinal disorders	
Ischemic colitis, acute pancreatitis	Rare
Intestinal obstruction	Uncommon
Infections and infestations	
Herpes meningoencephalitis, septic shock	Rare
Progressive multifocal leukoencephalopathy [a]	Very rare
Immune system disorders	
Angioedema	Rare
Anaphylactic reaction	Very rare
Nervous system disorders	
Encephalopathy, autonomic neuropathy, posterior reversible encephalopathy syndrome	Rare
Guillain-Barré syndrome, demyelinating polyneuropathy	Very rare
Respiratory, thoracic and mediastinal disorders	
Acute diffuse infiltrative pulmonary disease (see Special Warnings and Special Precautions for Use)	Rare
Pulmonary hypertension	Rare
Skin and subcutaneous tissue disorders	
Stevens-Johnson Syndrome and toxic epidermal necrolysis	Very rare
Acute febrile neutrophilic dermatosis (Sweet's syndrome)	Rare

[a] Very rare cases with unknown causality of John Cunningham (JC) virus infection, resulting in PML and death, have been reported in patients treated with VELCADE®.

Hepatitis B Virus (HBV) reactivation and infection

When rituximab is used in combination with VELCADE®, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment. Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with VELCADE®. Antiviral prophylaxis should be considered.

Overdose

Cardiovascular safety pharmacology studies in monkeys and dogs showed that IV doses approximately two to three times the recommended clinical dose on a mg/m^2 basis are associated with increases in heart rate, decreases in contractility, hypotension, and death. The decreased cardiac contractility and hypotension responded to acute intervention with positive inotropic or pressor agents. In dog studies, a slight increase in the corrected QT interval was observed at a lethal dose. In monkeys, doses of 3.0 mg/m^2 and greater (approximately twice the recommended clinical dose) resulted in hypotension starting at 1 hour post-administration, with progression to death in 12 to 14 hours following drug administration.

Overdosage more than twice the recommended dose in patients has been associated with the acute onset of symptomatic hypotension and thrombocytopenia with fatal outcomes.

There is no known specific antidote for VELCADE® overdosage. In the event of an overdosage, the patient's vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors and/or inotropic agents) and body temperature (see *Special Warnings and Special Precautions for Use* and *Posology and Method of Administration*).

Pharmacological Properties

Pharmacodynamic Properties

Mechanism of Action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types *in vitro*. Bortezomib causes a delay in tumor growth *in vivo* in nonclinical tumor models, including multiple myeloma.

Data from in vitro, ex vivo, and animal models with bortezomib suggest that it increases osteoblast differentiation and activity and inhibits osteoclast function. These effects have been observed in patients with multiple myeloma affected by an advanced osteolytic disease and treated with bortezomib.

Clinical Studies

Phase 2 Clinical Studies in Relapsed Multiple Myeloma

The safety and efficacy of VELCADE® IV in relapsed multiple myeloma were evaluated in an open-label, single-arm, multicenter study of 202 patients who had received at least 2 prior therapies and demonstrated disease progression on their most recent therapy. The median number of prior therapies was 6. Baseline patient and disease characteristics are summarized in **Table 13**.

An IV bolus injection of VELCADE® 1.3 mg/m^2/dose was administered twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21) for a maximum of 8 treatment cycles. The study employed dose modifications for toxicity (see *Posology and Method of Administration*). Patients who experienced a response to VELCADE® were allowed to continue VELCADE® treatment in an extension study.

Table 13: Summary of Patient Population and Disease Characteristicsin a Phase 2 Multiple Myeloma Study[a]

	N = 202
Patient Characteristics	
Median age in years (range)	59 (34, 84)
Gender: Male/female	60% / 40%
Race: Caucasian/black/other	81% / 10% /8%
Karnofsky Performance Status score ≤70	20%
Hemoglobin <100 g/L	44%
Platelet count <75 x 10^9/L	21%
Disease Characteristics	
Type of myeloma (%): IgG/IgA/Light chain	60% / 24% / 14%

Median β_2-microglobulin (mg/L)	3.5
Median creatinine clearance (mL/min)	73.9
Abnormal cytogenetics	35%
Chromosome 13 deletion	15%
Median Duration of Multiple Myeloma Since Diagnosis in Years	4.0
Previous Therapy	
Any prior steroids, e.g., dexamethasone, VAD	99%
Any prior alkylating agents, e.g., MP, VBMCP	92%
Any prior anthracyclines, e.g., VAD, mitoxantrone	81%
Any prior thalidomide therapy	83%
Received at least 2 of the above	98%
Received at least 3 of the above	92%
Received all 4 of the above	66%
Any prior stem cell transplant/other high-dose therapy	64%
Prior experimental or other types of therapy	44%

[a] Based on number of patients with baseline data available

Responses to VELCADE® alone are shown in **Table 14**. Response rates to VELCADE® alone were determined by an independent review committee (IRC) based on criteria published by Bladé and others. Complete response required <5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF^-). Response rates using the Southwest Oncology Group (SWOG) criteria are also shown. SWOG response required a ≥75% reduction in serum myeloma protein and/or ≥90% urine protein. A total of 188 patients were evaluable for response; 9 patients with nonmeasurable disease could not be evaluated for response by the IRC, and 5 patients were excluded from the efficacy analyses because they had minimal prior therapy.

Ninety-eight percent of study patients received a starting dose of 1.3 mg/m^2 administered IV. Twenty-eight percent of these patients received a dose of 1.3 mg/m^2 throughout the study, while 33% of patients who started at a dose of 1.3 mg/m^2 had to have their dose reduced during the study. Sixty-three percent of patients had at least one dose held during the study. In general, patients who had a confirmed CR received 2 additional cycles of VELCADE® treatment beyond confirmation. It was recommended that responding patients receive up to 8 cycles of VELCADE® therapy. The mean number of cycles administered was 6.

The median time to response was 38 days (range 30 to 127 days).
The median survival of all patients enrolled was 16 months (range <1 to 18+ months).

Table 14: Summary of Disease Outcomes in a Phase 2 Multiple Myeloma Study

Response Analyses (VELCADE® monotherapy) N = 188	**N (%)**	**(95% CI)**
Overall Response Rate (Bladé) (CR + PR)	52 (27.7%)	(21, 35)
Complete Response (CR)[a]	5 (2.7%)	(1, 6)
Partial Response (PR)[b]	47 (25%)	(19, 32)
Clinical Remission (SWOG)[c]	33 (17.6%)	(12, 24)
Kaplan-Meier Estimated Median Duration of Response (95% CI)	365 Days	(224, NE)

[a] Complete Response required < 5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF^-).

[b] Partial Response requires ≥50% reduction in serum myeloma protein and ≥ 90% reduction of urine myeloma protein on at least 2 occasions for a minimum of at least 6 weeks, stable bone disease and calcium.

[c] Clinical Remission (SWOG) required ≥75% reduction in serum myeloma protein and/or ≥90% reduction of urine myeloma protein on at least 2 occasions for a minimum of at least 6 weeks, stable bone disease and calcium.

Of the 202 patients enrolled, 35% were 65 years of age or older. Nineteen percent (19%) of patients aged 65 years or older experienced CR or PR.

In this study, the response rate to VELCADE®, based on a univariate analysis, was independent of the number and types of prior therapies. There was a decreased likelihood of response in patients with either >50% plasma cells or abnormal cytogenetics in the bone marrow. Responses were seen in patients with chromosome 13 abnormalities.

A small dose-response study was performed in 54 patients with multiple myeloma who received a 1.0 mg/m^2/dose or a 1.3 mg/m^2/dose twice weekly for two out of three weeks. A single complete response was seen at each dose, and there were overall (CR + PR) response rates of 30% (8/27) at 1.0 mg/m^2 and 38% (10/26) at 1.3 mg/m^2.

Patients who did not obtain an optimal response to therapy with VELCADE® alone (progressive or stable disease after 2 or 4 cycles, respectively) were able to receive high-dose dexamethasone in conjunction with VELCADE® (i.e., 40 mg dexamethasone with each dose of VELCADE® administered orally as 20 mg on the day of and 20 mg the day after VELCADE® administration, (i.e., Days 1, 2, 4, 5, 8, 9, 11, and 12), thus 160 mg over 3 weeks). A total of 74 patients were administered dexamethasone in combination with VELCADE® and were assessed for response. Eighteen percent (13/74) of patients achieved or had an improved response (CR 11% or PR 7%) with combination treatment.

Randomized, Open-Label, Phase 3 Clinical Study in Relapsed Multiple Myeloma comparing VELCADE® to Dexamethasone

A prospective phase 3, international, randomized (1:1), stratified, open-label clinical study enrolling 669 patients was designed to determine whether VELCADE® resulted in improvement in time to progression (TTP) compared to high-dose dexamethasone in patients with progressive multiple myeloma following 1 to 3 prior therapies. Patients considered to be refractory to prior high-dose dexamethasone were excluded as were those with baseline grade ≥2 peripheral neuropathy or platelet counts <50,000/μL. A total of 627 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had previously received (1 previous line versus more than 1 line of therapy), time of progression relative to prior treatment (progression during or within 6 months of stopping their most recent therapy versus relapse >6 months after receiving their most recent therapy), and screening β_2-microglobulin levels (≤2.5 mg/L versus >2.5 mg/L).

Baseline patient and disease characteristics are summarized in **Table 15**.

Table 15: Summary of Baseline Patient and Disease Characteristics in the Phase 3 Trial

Patient Characteristics	VELCADE® N=333	Dexamethasone N=336
Median age in years (range)	62.0 (33, 84)	61.0 (27, 86)

Gender: Male/female	56% / 44%	60% / 40%
Race: Caucasian/black/other	90% / 6% / 4%	88% / 7% / 5%
Karnofsky performance status score ≤70	13%	17%
Hemoglobin <100 g/L	32%	28%
Platelet count <75 x 10^9/L	6%	4%
Disease Characteristics		
Type of myeloma (%): IgG/IgA/Light chain	60% / 23% / 12%	59% / 24% / 13%
Median β_2-microglobulin (mg/L)	3.7	3.6
Median albumin (g/L)	39.0	39.0
Creatinine clearance ≤30 mL/min [n (%)]	17 (5%)	11 (3%)
Median Duration of Multiple Myeloma Since Diagnosis (Years)	3.5	3.1
Number of Prior Therapeutic Lines of Treatment		
Median	2	2
1 prior line	40%	35%
>1 prior line	60%	65%
All Patients	(N=333)	(N=336)
Any prior steroids, e.g., dexamethasone, VAD	98%	99%
Any prior anthracyclines, e.g., VAD, mitoxantrone	77%	76%
Any prior alkylating agents, e.g., MP, VBMCP	91%	92%
Any prior thalidomide therapy	48%	50%
Vinca alkaloids	74%	72%
Prior stem cell transplant/other high-dose therapy	67%	68%
Prior experimental or other types of therapy	3%	2%

Patients in the VELCADE® treatment group were to receive eight 3-week treatment cycles followed by three 5-week treatment cycles of VELCADE®. Within each 3-week treatment cycle, VELCADE® 1.3 mg/m^2/dose alone was administered by IV bolus twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21). Within each 5-week treatment cycle, VELCADE® 1.3 mg/m^2/dose alone was administered by IV bolus once weekly for 4 weeks on Days 1, 8, 15, and 22 followed by a 13-day rest period (Days 23 to 35) (see *Posology and Method of Administration*).

Patients in the dexamethasone treatment group were to receive four 5-week treatment cycles followed by five 4-week treatment cycles. Within each 5-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4, 9 to 12, and 17 to 20 followed by a 15-day rest period (Days 21-35). Within each 4-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4 followed by a 24-day rest period (Days 5 to 28). Patients with documented progressive disease on dexamethasone were offered VELCADE® at a standard dose and schedule on a companion study.

Following a preplanned interim analysis of time to progression, the dexamethasone arm was halted and all patients randomized to dexamethasone were offered VELCADE®, regardless of disease status. At this time of study termination, a final statistical analysis was performed. Due to this early termination of the study, the median duration of follow-up for surviving patients (n=534) is limited to 8.3 months.

In the VELCADE® arm, 34% of patients received at least one VELCADE® dose in all 8 of the 3-week cycles of therapy, and 13% received at least one dose in all 11 cycles. The average number of VELCADE® doses during the study was 22, with a range of 1 to 44. In the dexamethasone

arm, 40% of patients received at least one dose in all 4 of the 5-week treatment cycles of therapy, and 6% received at least one dose in all 9 cycles.

The time to event analyses and response rates from the phase 3 multiple myeloma study are presented in **Table 16**. Response and progression were assessed using the European Group for Blood and Marrow Transplantation (EBMT) criteria.[1] Complete response (CR) required <5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF^-). Partial Response (PR) requires ≥50% reduction in serum myeloma protein and ≥90% reduction of urine myeloma protein on at least 2 occasions for a minimum of at least 6 weeks along with stable bone disease and normal calcium. Near complete response (nCR) was defined as meeting all the criteria for complete response including 100% reduction in M-protein by protein electrophoresis, however M-protein was still detectable by immunofixation (IF^+).

Table 16: Summary of Efficacy Analyses in the Phase 3 Study

	All Patients		**1 Prior Line of Therapy**		**> 1 Prior Line of Therapy**	
	VELCADE®	**Dex**	**VELCADE®**	**Dex**	**VELCADE®**	**Dex**
Efficacy Endpoint	**n=333**	**n=336**	**n=132**	**n=119**	**n=200**	**n=217**
Time to Progression						
Events n (%)	147 (44)	196 (58)	55 (42)	64 (54)	92 (46)	132 (61)
Median [a] (95% CI)	6.2 mo (4.9, 6.9)	3.5 mo (2.9, 4.2)	7.0 mo (6.2, 8.8)	5.6 mo (3.4, 6.3)	4.9 mo (4.2, 6.3)	2.9 mo (2.8, 3.5)
Hazard ratio [b] (95% CI)	0.55 (0.44, 0.69)		0.55 (0.38, 0.81)		0.54 (0.41, 0.72)	
p-value [c]	<0.0001		0.0019		<0.0001	
Overall Survival						
Events (deaths) n (%)	51 (15)	84 (25)	12 (9)	24 (20)	39 (20)	60 (28)
Hazard ratio [b] (95% CI)	0.57 (0.40, 0.81)		0.39 (0.19, 0.81)		0.65 (0.43, 0.97)	
p-value [c,d]	<0.05		<0.05		<0.05	
Response Rate						
Population [e] n = 627	n=315	n=312	n=128	n=110	n=187	n=202
CR[f] n (%)	20 (6)	2 (<1)	8 (6)	2 (2)	12 (6)	0 (0)
PR[f] n(%)	101 (32)	54 (17)	49 (38)	27 (25)	52 (28)	27 (13)
nCR[f,g] n(%)	21 (7)	3 (<1)	8 (6)	2 (2)	13 (7)	1 (<1)
CR + PR[f] n (%)	121 (38)	56 (18)	57 (45)	29 (26)	64 (34)	27 (13)
p-value [h]	<0.0001		0.0035		<0.0001	
Median Response Duration						
CR[f]	9.9 mo	NE[i]	9.9 mo	NE	6.3 mo	NA[j]
nCR[f]	11.5 mo	9.2 mo	NE	NE	11.5 mo	9.2 mo
CR + PR[f]	8.0 mo	5.6 mo	8.1 mo	6.2 mo	7.8 mo	4.1 mo

[a] Kaplan-Meier estimate.

[b] Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for VELCADE®.

[c] p-value based on the stratified log-rank test including randomization stratification factors.

[d] Precise p-value cannot be rendered.

[e] Response population includes patients who had measurable disease at baseline and received at least 1 dose of study drug.

[f] EBMT criteria[1]; nCR meets all EBMT criteria for CR but has positive IF. Under EBMT criteria. nCR is in the PR category.

[g] In 2 patients, the IF was unknown.

[h] p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors.
[i] Not Estimable.
[j] Not Applicable, no patients in category.

Randomized, Open-Label Clinical Study in Relapsed Multiple Myeloma comparing VELCADE® IV and SC

An open-label, randomized, phase 3 non-inferiority study compared the efficacy and safety of the subcutaneous administration (SC) of VELCADE® versus the intravenous administration (IV). This study included 222 patients with relapsed multiple myeloma, who were randomized in a 2:1 ratio to receive 1.3 mg/m^2 of VELCADE® by either the SC or IV route for 8 cycles. Patients who did not obtain an optimal response (less than Complete Response (CR)) to therapy with VELCADE® alone after 4 cycles were allowed to receive dexamethasone 20 mg daily on the day of and after VELCADE® administration. Patients with baseline grade ≥ 2 peripheral neuropathy or platelet counts < 50000/µl were excluded. A total of 218 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had received (1 previous line versus more than 1 line of therapy), and international staging system (ISS) stage (incorporating beta2-microglobulin and albumin levels; Stages I, II, or III)
Baseline patient and disease characteristics are summarized in **Table 17**.

Table 17: Summary of Baseline Patient and Disease Characteristics in the Phase 3 Trial of VELCADE® IV vs SC

Patient Characteristics	**IV N = 74**	**SC N = 148**
Median age in years (range)	64.5 (38,86)	64.5 (42,88)
Gender: male/female	64% / 36%	50% / 50%
Race: Caucasian/Asian	96% / 4%	97% / 3%
Karnofsky performance status score ≤70	16%	22%
Disease Characteristics		
Type of myeloma (%): IgG/IgA/Light chain	72% / 19% / 8%	65% / 26% / 8%
ISS staging[a] I/II/III (%)	27/41/32	27/41/32
Median β_2-microglobulin (mg/l)	4.25	4.20
Median albumin (g/l)	3.60	3.55
Creatinine clearance ≤ 30 ml/min [n (%)]	2 (3%)	5 (3%)
Median Duration of Multiple Myeloma Since Diagnosis (Years)	2.93	2.68
Number of Prior Therapeutic Lines of Treatment		
1 prior line	65%	62%
> 1 prior line	35%	38%

[a] ISS Staging is derived from baseline central laboratory data.

This study met its primary objective of non-inferiority for response rate (CR + PR) after 4 cycles of single agent VELCADE® for both the SC and IV routes, 42% in both groups. In addition, secondary response-related and time to event related efficacy endpoints showed consistent results for SC and IV administration (**Table 18**).

Table 18: Summary of efficacy analyses for the SC administration of VELCADE® compared to IV

	IV VELCADE®	**SC VELCADE®**

Response-Evaluable Population[a]	**N = 73**		**N = 145**
Response Rate at 4 cycles			
ORR (CR+PR)	31 (42)		61 (42)
p-value[b]		0.00201	
CR n (%)	6(8)		9(6)
PR n (%)	25(34)		52(36)
nCR n (%)	4(5)		9(6)
Response Rate at 8 cycles			
ORR (CR+PR)	38(52)		76(52)
p-value[b]		0.0001	
CR n (%)	9 (12)		15 (10)
PR n (%)	29(40)		61(42)
nCR n (%)	7(10)		14(10)
Intent to Treat Population[c]	**N = 74**		**N = 148**
Median Time to Progression, months	9.4		10.4
(95% CI)	(7.6,10.6)		(8.5,11.7)
Hazard ratio (95% CI)[d]		0.839 (0.564,1.249)	
p-value (d)		0.38657	
Progression Free Survival, months	8.0		10.2
(95% CI)	(6.7,9.8)		(8.1,10.8)
Hazard ratio (95% CI)[d]		0.824 (0.574,1.183)	
p-value[e]		0.295	
1-year Overall Survival (%)[f]	76.7		72.6
(95% CI)	(64.1,85.4)		(63.1,80.0)

[a] All randomized subjects who received at least 1 non-zero dose of study medication and had measurable disease at study entry

[b] P-value is for the non-inferiority hypothesis that the SC arm retains at least 60% of the response rate in the IV arm.

[c] 222 subjects were enrolled into the study; 221 subjects were treated with VELCADE®

[d] Hazards ratio estimate is based on a Cox model adjusted for stratification factors: ISS staging and number of prior lines.

[e] Log-rank test adjusted for stratification factors: ISS staging and number of prior lines.

[f] Median duration of follow up is 11.8 months

Table 19 presents a cross-tabulation summary of best response by algorithm after 4 cycles versus after 8 cycles for patients who received dexamethasone. Eighty-two subjects in the SC treatment group and 39 subjects in the IV treatment group received dexamethasone after cycle 4.

Dexamethasone had a similar effect on improvement of response on both treatment arms:

- 30% (SC) and 30% (IV) of patients with no response at end of Cycle 4 obtained a response later.
- 13% (SC) and 13% (IV) of patients with PR at end of Cycle 4 obtained a CR later.

Table 19: Cross-tabulation of Summary of Best Response After 4 Cycles vs. After 8 Cycles for patients who received dexamethasone

---------- Best Response After 8 Cycles ----------
(N = 121)

Treatment Group	Total	---------- Category, n (%) ----------		
Cycle 4 Best Response[a]	n (%)	CR	PR	Non-responder
IV	39 (32)	3 (8)	20 (51)	16 (41)
CR	1 (1)	1 (100)	0	0
PR	15 (12)	2 (13)	13 (87)	0
Non-responder	23 (19)	0	7 (30)	16 (70)
SC	82 (68)	8 (10)	41 (50)	33 (40)
CR	4 (3)	4 (100)	0	0
PR	31 (26)	4 (13)	27 (87)	0
Non-responder	47 (39)	0	14 (30)	33 (70)

[a] Response assessment by validated computer algorithm. This algorithm incorporates a consistent assessment of all data required for response by the modified EBMT criteria.

Relative to previously reported outcomes, the ORR after 8 cycles of treatment (52% in both treatment groups) and time to progression (median 10.4 months and 9.4 months in SC and IV treatment groups, respectively), including the effect of the addition of dexamethasone from cycle 5 onwards, were higher than observed in prior registration study with single agent IV VELCADE® (38% ORR and median TTP of 6.2 months for the VELCADE® arm). Time to Progression and ORR was also higher compared to the subgroup of patients that received only 1 prior line of therapy (43% ORR and median TTP of 7.0 months) (**Table 16**).

TTP was statistically significantly longer on the VELCADE® arm (see Figure 1).

Figure 1: Time to Progression Bortezomib vs. Dexamethasone



* Patients remaining after the indicated timepoint
† p-value from log-rank test

As shown in Figure 2, VELCADE® had a significant survival advantage relative to dexamethasone ($p<0.05$). The median follow-up was 8.3 months.

Figure 2: Overall Survival Bortezomib vs. Dexamethasone



* Patients remaining after the indicated timepoint
† p-value from log-rank test

For the 121 patients achieving a response (CR or PR) on the VELCADE® arm, the median duration was 8.0 months (95% CI: 6.9, 11.5 months) compared to 5.6 months (95% CI: 4.8, 9.2 months) for the 56 responders on the dexamethasone arm. The response rate was significantly higher on the VELCADE® arm regardless of β_2-microglobulin levels at baseline.

A Randomized Phase 2 Dose-Response Study in Relapsed Multiple Myeloma

An open-label, multicenter study randomized 54 patients with multiple myeloma who had progressed or relapsed on or after front-line therapy to receive VELCADE® 1.0 mg/m^2 or 1.3 mg/m^2 IV bolus twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21). The median duration of time between diagnosis of multiple myeloma and first dose of VELCADE® on this trial was 2.0 years, and patients had received a median of 1 prior line of treatment (median of 3 prior therapies). A single complete response was seen at each dose. The overall response rates (CR + PR) were 30% (8/27) at 1.0 mg/m^2 and 38% (10/26) at 1.3 mg/m^2.

A Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma

Patients from the two phase 2 studies who in the investigators' opinion would experience additional clinical benefit continued to receive VELCADE® beyond 8 cycles on an extension study. Sixty-three (63) patients from the phase 2 multiple myeloma studies were enrolled and received a median of 7 additional cycles of VELCADE® therapy for a total median of 14 cycles (range 7 to 32). The overall median dosing intensity was the same in both the parent protocol and extension study. Sixty-seven percent (67%) of patients initiated the extension study at the same or higher dose intensity at which they completed the parent protocol, and 89% of patients maintained the standard 3-week-dosing schedule during the extension study. No new cumulative or new long-term toxicities were observed with prolonged VELCADE® treatment (see *Undesirable Effects*).

Randomized, Open-Label Clinical Study in Patients with Previously Untreated Multiple Myeloma

A prospective phase 3, international, randomized (1:1), open-label clinical study of 682 patients was conducted to determine whether VELCADE® (1.3 mg/m^2) in combination with melphalan (9 mg/m^2) and prednisone (60 mg/m^2) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m^2) and prednisone (60 mg/m^2) in patients with previously untreated multiple myeloma. This study included patients who were not candidates for stem cell transplant. Treatment was administered for a maximum of 9 cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity. Baseline demographics and patient characteristics are summarized in **Table 20**.

Table 20: Summary of Baseline Patient and Disease Characteristics in the VISTA Study

Patient Characteristics	**VMP N=344**	**MP N=338**
Median age in years (range)	71.0 (57, 90)	71.0 (48, 91)
Gender: male/female	51% / 49%	49% / 51%
Race: Caucasian/asian/black/other	88% / 10% / 1% / 1%	87% / 11% / 2% / 0%
Karnofsky performance status score ≤70	35%	33%
Hemoglobin <100 g/L	37%	36%
Platelet count <75 x 10^9/L	<1%	1%
Disease Characteristics		
Type of myeloma (%): IgG/IgA/Light chain	64% / 24% / 8%	62% / 26% / 8%
Median β_2-microglobulin (mg/L)	4.2	4.3
Median albumin (g/L)	33.0	33.0
Creatinine clearance ≤30 mL/min [n (%)]	20 (6%)	16 (5%)

At the time of a pre-specified interim analysis, the primary endpoint, time to progression, was met and patients in the MP arm were offered VcMP treatment. Median follow-up was 16.3 months. The final survival update was performed with a median duration of follow-up at 60.1 months. A statistically significant survival benefit in favor of the VcMP treatment group was observed (HR=0.695; p=0.00043) despite subsequent therapies that included VELCADE®-based regimens. The median survival in MP treatment group has been estimated at 43.1 months, and the median survival on the VcMP treatment group has been estimated at 56.4 months. Efficacy results are presented in **Table 21**.

Table 21: Summary of Efficacy Analyses in the VISTA study

Efficacy Endpoint	**VMP n=344**	**MP n=338**
Time to Progression – Events n (%)	101 (29)	152 (45)
Median[a] (95% CI)	20.7 mo (17.6, 24,7)	15.0 mo (14.1, 17.9)
Hazard ratio[b] (95% CI)	0.54 (0.42, 0.70)	
p-value [c]	0.000002	
Progression-free Survival Events n (%)	135 (39)	190 (56)
Median[a] (95% CI)	18.3 mo (16.6, 21.7)	14.0 mo (11.1, 15.0)
Hazard ratio[b] (95% CI)	0.61 (0.49, 0.76)	
p-value [c]	0.00001	
Overall Survival[h] Events (deaths) n (%)	176 (51.2)	211 (62.4)
Median[a] (95% CI)	56.4 mo (52.8, 60.9)	43.1 mo (35.3, 48.3)
Hazard ratio[b] (95% CI)	0.695 (0.567, 0.852)	
p-value [c]	0.00043	
Response Rate population[e] n = 668	n=337	n=331
CR[f] n (%)	102 (30)	12 (4)
PR[f] n (%)	136 (40)	103 (31)
nCR n (%)	5 (1)	0
CR + PR[f] n (%)	238 (71)	115 (35)
p-value[d]	$<10^{-10}$	
Reduction in Serum M-protein population[g] n=667	n=336	n=331
>=90% n (%)	151 (45)	34 (10)
Time to First Response in CR + PR		
Median	1.4 mo	4.2 mo
Median[a] Response Duration		
CR[f]	24.0 mo	12.8 mo
CR + PR[f]	19.9 mo	13.1 mo
Time to Next Therapy Events n (%)	224 (65.1)	260 (76.9)
Median[a] (95% CI)	27.0 mo (24.7, 31.1)	19.2 mo (17.0, 21.0)
Hazard ratio[b] (95% CI)	0.557 (0.462, 0.671)	
p-value [c]	(< 0.000001)	

Note: All results are based on the analysis performed at a median follow-up duration of 16.3 months except for the overall survival analysis that was performed at a median follow-up duration of 60.1 months.

[a] Kaplan-Meier estimate

[b] Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: beta2-microglobulin, albumin, and region. A hazard ratio less than 1 indicates an advantage for VMP

[c] Nominal p-value based on the stratified log-rank test adjusted for stratification factors: beta2-microglobulin, albumin, and region

[d] p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors
[e] Response population includes patients who had measurable disease at baseline
[f] EBMT criteria
[g] All randomized patients with secretory disease
[h] Survival update based on a median duration of follow-up at 60.1 months
NE: Not estimable

A Phase 2 Single-arm Clinical Study in Relapsed Mantle Cell Lymphoma After Prior Therapy

The safety and efficacy of VELCADE® in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study [M34103-053 (PINNACLE)] of 155 patients with progressive disease who had received at least 1 prior therapy. VELCADE® was administered at the recommended dose of 1.3 mg/m^2. The median number of cycles administered across all patients was 4 (range 1-17); and 8 in responding patients. Response rates to VELCADE® are described in **Table 22**.

Table 22: Summary of Disease Outcomes in a Phase 2 Mantle Cell Lymphoma Study

[a]Response Analyses (N = 141)	N (%)	95% CI
Overall Response Rate (IWRC) (CR + CRu + PR)	47 (33)	(26, 42)
Complete Response (CR + CRu)	11 (8)	(4, 14)
CR	9 (6)	(3, 12)
Cru	2 (1)	(0, 5)
Partial Response (PR)	36 (26)	(19, 34)
Time to Event Analyses	Median	95% CI
Kaplan-Meier Estimated Duration of Response		
CR + CRu + PR (N = 47)	9.2 months	(4.9, 13.5)
CR + CRu (N = 11)	13.5 months	(13.5, NE)
Kaplan-Meier Estimated Time to Progression (N = 155)	6.2 months	(4.0, 6.9)
**Kaplan-Meier Estimated Treatment Free Interval, CR + CRu (N = 11)	13.8 months	(13.4, NE)
Median Time to Next Treatment		
CR + CRu + PR (N = 47)	12.7 months	(9.33, NE)
CR+CRu (N=11)	19.4 months	(17.8, NE)

[a] Based on International Response Workshop Criteria (IRWC).
CRu = Complete Response unconfirmed
NE=not estimable**Additional analyses

With a median duration of follow-up of more than 13 months in surviving patients, the median survival had not yet been reached and the Kaplan-Meier estimate of 1-year survival was 69%. The Kaplan-Meier estimate of 1-year survival was 94% in responders and 100% in those achieving CR or CRu.

Previously Untreated Mantle Cell Lymphoma

A randomized, open-label, Phase 3 study (LYM-3002) was conducted in 487 adult patients with previously untreated mantle cell lymphoma (Stage II, III or IV) to determine whether VELCADE® administered in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) resulted in improvement in progression free survival (PFS) when compared to the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and

prednisone (R-CHOP). This clinical study utilized independent pathology confirmation and independent radiologic response assessment.

Patients in the VcR-CAP treatment arm received VELCADE® (1.3 mg/m^2) administered intravenously on Days 1, 4, 8, and 11 (rest period Days 12-21); rituximab (375 mg/m^2) on Day 1; cyclophosphamide (750 mg/m^2) on Day 1; doxorubicin (50 mg/m^2) on Day 1; and prednisone (100 mg/m^2) on Day 1 through Day 5 of the 21-day treatment cycle. For patients with a response first documented at Cycle 6, two additional treatment cycles were given.

Median patient age was 66 years, 74% were male, 66% were Caucasian and 32% were Asian. 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 35% of patients had an International Prognostic Index (IPI) score of 3 (high-intermediate) and 74% had Stage IV disease. Median number of cycles received by patients in both treatment arms was 6 with 17% of patients in the R-CHOP group and 14% of subjects in the VcR-CAP group receiving up to 2 additional cycles. The majority of the patients in both groups received 6 or more cycles of treatment, 83% in the R-CHOP group and 84% in the VcR-CAP group.

The primary efficacy endpoint was progression-free survival based on Independent Review Committee (IRC) assessment. Secondary endpoints included, time to progression (TTP), time to next anti-lymphoma treatment (TNT), duration of treatment free interval (TFI), overall response rate (ORR) and complete response (CR/CRu) rate, overall survival (OS) and response duration. The response criteria used to assess efficacy were based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (IWRC)[6].

A statistically significant benefit in favor of the VcR-CAP treatment group was observed for PFS, TTP, TNT, TFI overall complete response rate, and overall survival. At a median follow-up of 40 months, a 59% improvement in the primary endpoint of PFS (Hazard Ratio [HR]=0.63; $p < 0.001$) was observed in the Vc-RCAP group (median=24.7 months) as compared to the R-CHOP group (median=14.4 months). The median duration of complete response was more than double in the VcR-CAP group (42.1 months) compared with the R-CHOP group (18 months) and the duration of overall response was 21.4 months longer in the VcR-CAP group. At a median follow-up of 40 months, median OS (56.3 months in the R-CHOP group, and not reached in the VcR-CAP group) favored the VcR-CAP group, (estimated HR=0.80; p=0.173). There was a trend towards prolonged overall survival favoring the VcR-CAP group; the estimated 4-year survival rate was 53.9% in the R-CHOP group and 64.4% in the VcR-CAP group.

The final analysis for OS was performed after a median follow-up of 82 months. Median OS in the VR-CAP group was 90.7 months, almost three years more than the OS achieved in the R-CHOP group, which was 55.7 months (HR=0.66; p=0.001).

Efficacy results are presented in **Table 23**.

Table 23: Summary of Efficacy Outcomes in a Phase 3 Mantle Cell Lymphoma Study in Previously Untreated Patients (LYM-3002)

Efficacy endpoint	**VcR-CAP**	**R-CHOP**	
n: ITT patients	243	244	
Progression free survival (IRC)[a]			
Events n (%)	133 (54.7)	165 (67.6)	HR[d](95% CI)=0.63 (0.50;0.79)

Efficacy endpoint	**VcR-CAP**	**R-CHOP**	
Median[c] (95% CI) (months)	24.7 (19.8; 31.8)	14.4 (12; 16.9)	p-value[e] < 0.001
Progression free survival (Investigator)[b]			
Events n (%)	128 (52.7)	179 (73.4)	HR[d](95% CI)=0.51 (0.41; 0.65)
Median[c] (95% CI) (months)	30.7 (25.1; 37.3)	16.1 (14.0; 18.4)	p-value[e] < 0.001
Time to Progression[a]			
Events n (%)	114 (46.9)	148 (60.7)	HR[d](95% CI)=0.58 (0.45;0.74)
Median[c](95% CI) (months)	30.5 (22.9; 40.9)	16.1(13.7;18.1)	p-value[e] < 0.001
Time to Next Anti-lymphoma Therapy			
Events n (%)	94 (38.7)	145 (59.4)	HR[d] (95% CI)=0.50 (0.38;0.65)
Median[c] (95% CI) (months)	44.5 (38.8; NE)	24.8 (22.1; 27.5)	p-value[e] < 0.001
Treatment Free Interval			
n :All Treated Patients	240	242	
Events n (%)	93 (38.8)	145 (59.9)	HR[d] (95% CI)=0.50 (0.38; 0.65)
Median[c] (95% CI) (months)	40.6 (33.6; NE)	20.5 (17.8; 22.8)	p-value[e] < 0.001
Overall survival at a median follow-up of 82 months			
n :ITT patients	243	244	
Events n (%)	103 (42.4)	138 (56.6)	HR[d] (95% CI)=0.66 (0.51; 0.85)
Median[c](95% CI) (months)	90.7 (71.4; NE)	55.7 (47.2; 68.9)	p-value[e] =0.001
Response Rate			
n : response-evaluable patients	229	228	
Overall complete response (CR+CRu)[h] n(%)	122 (53.3)	95(41.7)	OR[f](95% CI)=1.688 (1.148; 2.481) p-value[g] =0.007
Overall radiological response (CR+CRu+PR)[i] n(%)	211 (92.1)	204 (89.5)	OR[f](95% CI)=1.428 (0.749; 2.722) p-value[g] =0.275
Response Duration			
Duration of complete response (CR+CRu)[j]			
n = response-evaluable patients	122	95	
Median[c] (95% CI) (months)	42.1 (30.7; 49.1)	18.0 (14.0; 23.4)	
Duration of Response (CR+CRu+PR)[k]			
n: response-evaluable subjects	211	204	
Median[c] (95% CI) (months)	36.5 (26.7; 46.7)	15.1 (12.5; 17.0)	

Note: All results are based on the analysis performed at a median follow-up duration of 40 months except for the overall survival analysis.

[a] Based on IRC assessment (radiological data only).

[b] Based on Investigator assessment.

[c] Based on Kaplan-Meier product limit estimates.

[d] Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease. A hazard ratio < 1 indicates an advantage for VcR-CAP.

[e] Based on Log-rank test stratified with IPI risk and stage of disease.

[f] Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and Stage of Disease as stratification factors. An odds ratio (OR) > 1 indicates an advantage for VcR-CAP.

[g] P-value from the Cochran Mantel-Haenszel Chi-Squared test, with IPI and Stage of Disease as stratification factors.

[h] Include all CR + CRu, by IRC, bone marrow and LDH.

[i] Include all radiological CR+CRu+PR by IRC regardless the verification by bone marrow and LDH.

[j] Calculated from first date of complete response (CR+CRu by IRC, bone marrow and LDH) to date of PD or death due to PD.

[k] Calculated from first date of response (include all radiological CR+CRu+PR by IRC) to date of PD or death due to PD.

IRC=Independent Review Committee; IPI=International Prognostic Index; LDH = Lactate dehydrogenase; CR=Complete Response; CRu= Complete response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=hazard ratio; OR= odds ratio; ITT= intent to treat; PD=Progressive disease

Patients with Previously Treated Light-Chain (AL) Amyloidosis
A Phase 1/2 study was conducted to determine the safety and efficacy of VELCADE® in patients with previously treated light-chain (AL) Amyloidosis. No new safety concerns were observed during the study, and in particular VELCADE® did not exacerbate target organ damage (heart, kidney and liver). In 49 evaluable patients treated at 1.6 mg/m^2 weekly or 1.3 mg/m^2 twice weekly, a 67.3% response rate (including a 28.6% CR rate) as measured by haematological response (M- protein) was reported. For these dose cohorts, the combined 1-year survival rate was 88.1%.

Pediatric Use
The safety and effectiveness of VELCADE® in pediatric patients has not been established for multiple myeloma and mantle cell lymphoma.

Geriatric Use
Of the 669 patients enrolled in the phase 3 multiple myeloma study, 245 (37%) were 65 years of age or older: 125 (38%) on the VELCADE® arm and 120 (36%) on dexamethasone arm. Median time to progression and median duration of response for patients ≥65 were longer on VELCADE® compared to dexamethasone [5.5 mo versus 4.3 mo, and 8.0 mo versus 4.9 mo, respectively]. On the VELCADE® arm, 40% (n=46) of evaluable patients aged ≥65 experienced response (CR+PR) versus 18% (n=21) on the dexamethasone arm. The incidence of Grade 3 and 4 events was 64%, 78% and 75% for VELCADE® patients ≤50, 51-64 and ≥65 years old, respectively (see *Clinical Trials*).

In the phase 2 clinical study of 202 patients with relapsed multiple myeloma, 35% of patients were 65 years of age or older, the incidence of Grade ≥3 events was 74%, 80%, and 85% for VELCADE® patients ≤50, 51 to 65, and >65 years old, respectively (see *Clinical Trials*).

No overall differences in safety or effectiveness were observed between patients ≥ age 65 and younger patients receiving VELCADE®; but greater sensitivity of some older individuals cannot be ruled out.

Pharmacokinetic Properties
Pharmacokinetics
Following intravenous bolus administration of a 1.0 mg/m² and 1.3 mg/m^2 dose to eleven patients with multiple myeloma, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/mL respectively. In subsequent doses, when administered twice weekly, the mean maximum observed plasma concentrations ranged from 67 to 106ng/mL for the 1.0mg/m² dose and 89 to 120ng/mL for the 1.3mg/m² dose. The mean elimination half-life of bortezomib upon multiple dosing ranged from 40-193 hours after the 1.0mg/m² and 76 to 108 hours after the 1.3mg/m² dose. Bortezomib is eliminated more rapidly following the first dose compared to subsequent doses. Mean total clearances were 102 and 112L/h following the first dose for doses of 1.0mg/m² and 1.3mg/m², respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1.0mg/m² and 1.3mg/m², respectively.

In the PK/PD substudy in Phase 3 trial, following an IV bolus or subcutaneous (SC) injection of a 1.3 mg/m^2 dose to multiple myeloma patients (n = 14 for IV, n = 17 for SC) , the total systemic exposure after repeat dose administration (AUC_{last}) was equivalent for SC and IV administration. The C_{max} after SC administration (20.4 ng/ml) was lower than IV (223 ng/ml). The AUC_{last} geometric mean ratio was 0.99 and 90% confidence intervals were 80.18% - 122.80%.

Distribution

The mean distribution volume of bortezomib ranged from 1659 liters to 3294 liters (489 to 1884L/m²) following single or repeat dose IV administration of 1.0mg/m² or 1.3mg/m² to patients with multiple myeloma. This suggests that bortezomib distributes widely to peripheral tissues. The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL.

Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2. Bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated bortezomib metabolites are inactive as 26S proteasome inhibitors. Pooled plasma data from 8 patients at 10 min and 30 min after IV dosing indicate that the plasma levels of metabolites are low compared to the parent drug.

Elimination

The pathways of elimination of bortezomib have not been characterized in humans.

Special Populations

Age, Gender, and Race

Based on a population pharmacokinetic analysis, clearance of bortezomib increased with increasing body surface area (BSA). Geometric mean (%CV) clearance was 7.79 (25%) L/hr/m^2, volume of distribution at steady-state was 834 (39%) L/m^2, and the elimination half-life was 100 (44%) hours. After correcting for the BSA effect, other demographics such as age, body weight and sex did not have clinically significant effects on bortezomib clearance. BSA-normalized clearance of bortezomib in pediatric patients was similar to that observed in adults.

The effects of gender and race on pharmacokinetics of bortezomib have not been evaluated.

Hepatic Impairment

The effect of hepatic impairment on the pharmacokinetics of IV bortezomib was assessed in 60 cancer patients at bortezomib doses ranging from 0.5 to 1.3 mg/m^2. When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalized bortezomib AUC. However, the dose-normalized mean AUC values were increased by approximately 60% in patients with moderate or severe hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment, and those patients should be monitored closely (See **Table 5**).

Renal Impairment
A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL ≥60 mL/min/1.73 m^2, n=12), Mild (CrCL=40-59 mL/min/1.73 m^2, n=10), Moderate (CrCL=20-39 mL/min/1.73 m^2, n=9), and Severe (CrCL < 20 mL/min/1.73 m^2, n=3). A group of dialysis patients who were dosed after dialysis was also included in the study (n=8). Patients were administered intravenous doses of 0.7 to 1.3 mg/m^2 of bortezomib twice weekly. Exposure of bortezomib (dose-normalized AUC and Cmax) was comparable among all the groups (see *Posology and Method of Administration*).

Preclinical Safety Data
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies have not been conducted with bortezomib.

Bortezomib showed clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary cells. Bortezomib was not genotoxic when tested in the in vitro mutagenicity assay (Ames test) and in vivo micronucleus assay in mice.

Fertility studies with bortezomib were not performed but evaluation of reproductive tissues has been performed in the general toxicity studies. In the 6-month rat toxicity study, degenerative effects in the ovary were observed at doses ≥0.3 mg/m^2 (one-fourth of the recommended clinical dose), and degenerative changes in the testes occurred at 1.2 mg/m^2. VELCADE® could have a potential effect on either male or female fertility.

Animal Toxicity Findings
Cardiovascular Toxicity
Studies in monkeys showed that administration of dosages approximately twice the recommended clinical dose resulted in heart rate elevations, followed by profound progressive hypotension, bradycardia, and death 12 to 14 hours post dose. Doses ≥1.2 mg/m^2 induced dose-proportional changes in cardiac parameters. Bortezomib has been shown to distribute to most tissues in the body, including the myocardium. In a repeated dosing toxicity study in the monkey, myocardial hemorrhage, inflammation, and necrosis were also observed.

Chronic Administration
In animal studies at a dose and schedule similar to that recommended for patients (twice weekly dosing for 2 weeks followed by 1-week rest), toxicities observed included severe anemia and thrombocytopenia, and gastrointestinal, neurological and lymphoid system toxicities. Neurotoxic effects of bortezomib in animal studies included axonal swelling and degeneration in peripheral nerves, dorsal spinal roots, and tracts of the spinal cord. Additionally, multifocal hemorrhage and necrosis in the brain, eye, and heart were observed.

PHARMACEUTICAL INFORMATION
List of Excipients
Mannitol (E421)

Incompatibilities
This product must not be mixed with other medicinal products except those mentioned in Instructions for Use and Handing and Disposal.

Shelf Life
Refer to outer carton.

Unopened vials of VELCADE® are stable until the date indicated on the package when stored in the original package protected from light.

Storage Conditions
VELCADE® contains no antimicrobial preservative. When reconstituted as directed, VELCADE® may be stored up to 25ºC (77ºF). Reconstituted VELCADE® should be administered within 8 hours of preparation. The reconstituted material may be stored for up to 8 hours in the original vial or in a syringe prior to administration. The total storage time for the reconstituted material must not exceed 8 hours when exposed to normal indoor lighting.

Do not store unopened vials above 30°C. Retain in original package to protect from light.

Keep out of reach of children.

Nature and Contents of Container
Ten (10) mL, type 1, glass vial with a gray bromobutyl stopper and aluminum seal. The cap color of the 10 mL vial is royal blue. Each vial is contained in a transparent blister pack consisting of a tray with a lid. The 10 mL vial contains 38.5 mg powder for solution for injection.

VELCADE® is available in cartons containing 1 single use vial.

Instructions for Use and Handling and Disposal
Administration Precautions
VELCADE® is an antineoplastic. Caution should be used during handling and preparation including careful dose calculation to prevent overdose. The drug quantity contained in one vial (3.5 mg) may exceed the usual single dose required. Proper aseptic technique should be used. Use of gloves and other protective clothing to prevent skin contact is recommended. In clinical trials, local skin irritation was reported in 5% of patients, but extravasation of VELCADE® was not associated with tissue damage.

When administered subcutaneously, alternate sites for each injection (thigh or abdomen). New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, red, or hard.

There have been fatal cases of inadvertent intrathecal administration of VELCADE®. VELCADE® is for IV and SUBCUTANEOUS use only. **DO NOT ADMINISTER VELCADE® INTRATHECALLY.**

Reconstitution/Preparation for Intravenous and Subcutaneous Administration

The contents of each vial should be reconstituted only with normal (0.9%) saline according to the following instructions based on route of administration:

	IV	SC
Volume of diluent (0.9% Sodium Chloride) added to reconstitute one vial	3.5 ml	1.4 ml
Final Concentration after reconstitution (mg/ml)	1.0 mg/ml	2.5 mg/ml

Stickers that indicate the prescribed route of administration and concentration on a sticker card are provided with each VELCADE® vial. These stickers should be placed directly on the syringe and vial of VELCADE® once VELCADE® is prepared to ensure the correct route of administration.

The reconstituted product should be a clear and colorless solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If any discoloration or particulate matter is observed, the reconstituted product should not be used.

Procedure for Proper Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

PRODUCT REGISTRANT

Johnson & Johnson International (Singapore) Pte. Ltd.
2 Science Park Drive
#07-13, Ascent
Singapore Science Park 1
Singapore 118222

BATCH RELEASER

Janssen Pharmaceutica NV,
Turnhoutseweg 30,
B-2340,
Beerse,
Belgium

LAST DATE OF REVISION OF THE TEXT

11 November 2022 (CCDS 25 February 2021)